Sign Up Today and Learn More About Sirius Therapeutics Stock
Invest in or calculate the value of your shares in Sirius Therapeutics or other pre-IPO companies through EquityZen's platform.
Sirius Therapeutics Stock (SIRT)
Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases.
About Sirius Therapeutics Stock
Founded
2021
Headquarters
San Diego, CA, US
Industries
Messaging and Telecommunications, Sports, Content and Publishing
Sirius Therapeutics Press Mentions
Stay in the know about the latest news on Sirius Therapeutics
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
businesswire • Dec 10, 2024
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
morningstar • Dec 10, 2024
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
biospace • Dec 10, 2024
From Bebest Automotive Electronics to Yuan Planet, Chinese companies on Forbes Asia's 100 to Watch list
forbesindia • Nov 15, 2024
Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next ...
finance • May 05, 2024
Join now and verify your accreditation status to gain access to:
- Sirius Therapeutics Current Valuation
- Sirius Therapeutics Stock Price
- Sirius Therapeutics Management
- Available deals in Sirius Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Sirius Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Sirius Therapeutics Revenue and Financials
- Sirius Therapeutics Highlights
- Sirius Therapeutics Business Model
- Sirius Therapeutics Risk Factors
- Sirius Therapeutics Research Report from SACRA Research
Trading Sirius Therapeutics Stock
How to invest in Sirius Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Sirius Therapeutics through EquityZen funds. These investments are made available by existing Sirius Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Sirius Therapeutics stock?
Shareholders can sell their Sirius Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
